|
|
|
Sunday, March 2, 2008 — 1:30 PM, Convention Center 201/203
|
- Evolving Concepts in Musculoskeletal Tumors
|
|
Moderator:
|
Angelo P. Dei Tos, General Hospital of Treviso, Treviso, Italy
|
|
|
Disclosure:
|
In accordance with ACCME guidelines regarding disclosure, the USCAP policy requires that faculty members who have a significant financial or other relationship with a commercial company, entity, or service (which will be discussed in this Symposium) must disclose this to attendees. The Academy also requires that speakers disclose any products that are not labeled for the use under discussion. Dr. Christopher L. Corless indicated he is a consultant and receives grant/research support for Novartis Pharma. Dr. Corless also has other financial interest in Pfizer (Consultant) and Transgenomic (Consultant). All other faculty members for this Symposium have indicated they have no disclosures to make.
|
Click the button above to add this event to your Itinerary Planner...
 Click here to view (or print) handout in single page format for the entire meeting.
Note: Any slides will be printed in color.
Click any blue title below to display and print the handout for individual lecture(s):
| 1:30 | Prognostication in Soft Tissue Sarcomas - Where do
we stand? - Louis Guillou, University of Lausanne, Switzerland |
| 2:00 | Epithelioid Vascular Tumors of Bone and Soft Tissue - Andrew
Rosenberg, Massachusetts General Hospital, Boston, MA |
| 2:30 | Cartilaginous Tumors: Lessons From Normal Chondrogenesis - Judith
Bovee, Leiden University School of Medicine, Leiden, The Netherlands |
| 3:00 | Break |
| 3:30 | The Role and Relevance of Mutational Analysis in GIST - Christopher L. Corless, Oregon
Health and Science University Cancer Institute, Portland, OR |
| 4:00 | The Role of Pathology in the Treatment of Sarcomas: From Grading to
Histotyping - Angelo Paolo Dei Tos, General Hospital of Treviso, Treviso, Italy |
| 4:30 | The Evolution of Soft Tissue Tumor Taxonomy: What Still Needs to be
Done? - Christopher D.M. Fletcher, Brigham & Women's Hospital, Harvard Medical School,
Boston, MA |
|
Topics are proposed and then selected by the Society's officers considering timeliness as well as
impact over bone and soft tissue tumor pathology practice. In consideration of the recent conceptual
evolution, special attention is given to the integration of conventional morphology with molecular
genetics. This meeting will therefore include some of the more recent developments in bone and soft
tissue pathology, trying to link both conventional and molecular diagnostic practice to both
prognostication and prediction of response to treatment. |
|
|
|
